Lonitoclax

Lonitoclax
Clinical data
Other names	ZE50-0134
Identifiers
	IUPAC name 5-[5-chloro-2-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]phenyl]-N-(4-hydroxyphenyl)-N-[(3-methoxy-2-methylphenyl)methyl]-1,2-dimethylpyrrole-3-carboxamide;
CAS Number	2952589-57-8;
PubChem CID	168969724;
ChemSpider	133325962;
UNII	76NBC3X6A3;
Chemical and physical data
Formula	C43H45ClN4O5
Molar mass	733.31 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC=C1OC)CN(C2=CC=C(C=C2)O)C(=O)C3=C(N(C(=C3)C4=C(C=CC(=C4)Cl)C(=O)N5CC6=CC=CC=C6C[C@H]5CN7CCOCC7)C)C;
	InChI InChI=InChI=1S/C43H45ClN4O5/c1-28-31(10-7-11-41(28)52-4)25-47(34-13-15-36(49)16-14-34)43(51)38-24-40(45(3)29(38)2)39-23-33(44)12-17-37(39)42(50)48-26-32-9-6-5-8-30(32)22-35(48)27-46-18-20-53-21-19-46/h5-17,23-24,35,49H,18-22,25-27H2,1-4H3/t35-/m0/s1; Key:CEWHUBSABMOQQC-DHUJRADRSA-N;

Lonitoclax is an investigational new drug that is being evaluated by Lomond Therapeutics for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukaemia (CML). It acts as an Bcl-2 inhibitor.^[1]^[2]

References

↑ "Lonitoclax - Lomond Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Byrd J, Ledwith B, Pickersgill F, Dokukina K, Karapetian R, Sharpe C, et al. (November 2025). "A novel: Plasma apoptosis assay to demonstrate CLL cell target engagement in first-in-human study of a highly selective oral bcl-2 inhibitor lonitoclax (ZE50-0134)". Blood. 146 6819. doi:10.1182/blood-2025-6819.